Pandora (NYSE:P): Pacific Crest recommends buying Pandora at current levels, saying that the company can grow its earnings per share meaningfully by increasing its margins and monetization. The firm reiterates a $17 price target and Outperform rating.
Sarepta Therapeutics (NASDAQ:SRPT): According to RW Baird, the U.S. Food and Drug Administration’s request for additional information from Sarepta may delay things, but should be viewed as a positive. According to the firm, the language in the minutes increases its confidence in a path to accelerated approval and signals an openness on the FDA’s part. An additional Phase 3 study does not appear to be needed, it adds. The firm has an Outperform rating and a $63 price target.
SM Energy (NYSE:SM): SM Energy’s new discovery is not priced into shares, according to Cowen, which believes the positive exploration success in the Woodbine formation will have a positive impact. Shares are Buy rated, with a $70 price target.
Citigroup (NYSE:C): Citigroup’s higher-than-expected EPS bodes well for the future, according to Wells Fargo. The firm believes that the company is benefiting from improving mortgage trends and thinks the chances that it will report higher profitability in the second half of the year have increased. It also believes the company can return more capital to investors in 2014, and keeps an Outperform rating.
Investing Insights: Will Baidu Resume Its Uptrend?